Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions.
Vaginal atrophy is the thinning, drying, and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning and urgency with urination, urinary tract infections, and urinary incontinence. Risk factors include smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.
The Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) drugs in development market research report provide comprehensive information on the therapeutics under development for Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Azure Biotech IncDare Bioscience Inc
Iaterion Inc
Lee's Pharmaceutical Holdings Ltd
Mithra Pharmaceuticals SA
Navad Life Sciences Pte Ltd
Profem GmbH
Sichuan Anaerobic Biotechnology Co Ltd
VaRi Bioscience GmbH
Table of Contents
Table
Figures
Frequently asked questions